Edition:
India

Savara Inc (SVRA.OQ)

SVRA.OQ on NASDAQ Stock Exchange Global Select Market

6.79USD
19 Feb 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$6.79
Open
$6.89
Day's High
$6.93
Day's Low
$6.62
Volume
36,129
Avg. Vol
50,619
52-wk High
$14.06
52-wk Low
$6.22

Latest Key Developments (Source: Significant Developments)

Savara Inc Remains On Track To Report Top Line Results From Impala At End Of Q2 2019
Wednesday, 6 Feb 2019 

Feb 6 (Reuters) - Savara Inc ::SAVARA PROVIDES UPDATE ON IMPALA AND AVAIL PIVOTAL CLINICAL STUDIES.SAVARA INC - REMAIN ON TRACK TO REPORT TOP LINE RESULTS FROM IMPALA AT END OF Q2 2019.SAVARA INC - EXPECTS TO COMPLETE ENROLLMENT FOR AVAIL STUDY IN Q3 OF 2019.SAVARA INC - TOP LINE DATA FROM AVAIL IS CURRENTLY EXPECTED IN Q2 OF 2020.SAVARA INC - "ROBUST RESULTS FROM IMPALA WOULD FACILITATE SUBMISSION OF A BIOLOGICS LICENSE APPLICATION (BLA) IN FIRST HALF OF 2020".  Full Article

Savara Provides Enrollment Update On Molgradex Impala
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Savara Inc ::SAVARA PROVIDES ENROLLMENT UPDATE ON MOLGRADEX IMPALA AND OPTIMA CLINICAL STUDIES AND REAFFIRMS GUIDANCE FOR TOPLINE DATA.SAVARA - INTERIM RESULTS FROM OPTIMA STUDY ARE STILL ON TRACK TO BE REPORTED IN Q4 2018 AND TOPLINE DATA IS ANTICIPATED IN Q2 2019.SAVARA INC - PATIENT ENROLLMENT IN IMPALA STUDY IS CURRENTLY AT 129 PATIENTS OUT OF A TOTAL TARGET OF 135 PATIENTS.  Full Article

Savara Provides Positive Update On Preparations Of Molgradex
Thursday, 26 Jul 2018 

July 25 (Reuters) - Savara Inc ::SAVARA PROVIDES POSITIVE UPDATE ON DEVELOPMENT AND COMMERCIAL PREPARATIONS OF MOLGRADEX, INCLUDING EXPANSION INTO NTM IN CF.SAVARA INC - COMPLETION OF PATIENT ENROLLMENT FOR PHASE 3 IMPALA STUDY REMAINS ON TRACK FOR Q3 2018 AND TOPLINE DATA ARE ANTICIPATED IN Q2 2019.SAVARA INC - EXPECTS SUBMISSION OF MOLGRADEX BLA, IN FIRST HALF OF 2020, WITH AN ANTICIPATED COMMERCIAL LAUNCH IN LATE 2020 OR EARLY 2021.SAVARA INC - ANNOUNCED ACQUISITION OF ASSETS OF CARDEAS PHARMA CORPORATION.  Full Article

Savara Amends Research Collaboration & License Agreement With Pari Pharma Dated Nov 7, 2014
Monday, 23 Jul 2018 

July 23 (Reuters) - Savara Inc ::SAVARA - AMENDMENT TO RESEARCH COLLABORATION & LICENSE AGREEMENT BETWEEN CO, PARI PHARMA DATED NOV 7, 2014.SAVARA - AMENDMENT ADDS NTB LUNG INFECTION TO INDICATIONS INCLUDED IN LICENSE.SAVARA INC - AMENDMENT ALLOWS CO TO ADD OTHER PULMONARY INFECTIONS TO INCLUDED INDICATIONS IN FUTURE.SAVARA - AMENDMENT EXPANDS DEVELOPMENT MILESTONES IN AGREEMENT TO INCLUDE NTM & ANY ADDITIONAL PULMONARY INDICATIONS.  Full Article

Savara Inc Files For Mixed Shelf Of Up To $250 Million
Saturday, 30 Jun 2018 

June 29 (Reuters) - Savara Inc ::SAVARA INC FILES FOR MIXED SHELF OF UP TO $250 MILLION – SEC FILING.  Full Article

Savara Inc - Development Award Raised to $6.7 Mln - Sec Filing
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Savara Inc ::SAVARA- ON NOV 28 ENTERED INTO AMENDMENT EFFECTIVE SEPT 30,TO RESEARCH PROGRAM AWARD LETTER AGREEMENT BETWEEN CO, CYSTIC FIBROSIS FOUNDATION THERAPEUTICS.SAVARA INC - UNDER AMENDMENT, AMOUNT OF DEVELOPMENT AWARD AVAILABLE TO SAVARA WAS INCREASED BY $5 MILLION TO AN AGGREGATE OF $6.7 MILLION - SEC FILING.  Full Article

Savara ‍Received $5 Mln Award For Development Of Aerovanc​
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Savara Inc ::SAVARA INC - ‍RECEIVED $5 MILLION AWARD FROM CYSTIC FIBROSIS FOUNDATION THERAPEUTICS FOR DEVELOPMENT OF AEROVANC​.  Full Article

Savara posts Q3 loss per share $0.28
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Savara Inc :Savara reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.28.Q3 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S.Anticipating complete enrollment in molgradex phase 3 impala study in q1 2018​.Initiating phase 2A study of Molgradex for treatment of NTM in early 2018​.Expecting top-line results from aironite phase 2 indie study in h1 2018​.Research and development expenses were $5.0 million for three-months ended September 30, 2017, compared with $2.1 million for Q3 of 2016​.  Full Article

SAVARA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Savara Inc ::SAVARA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAVARA INC - ‍PRICES UNDERWRITTEN PUBLIC OFFERING OF 5.25 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $7.85 PER SHARE​.  Full Article

Savara announces proposed public offering of common stock
Wednesday, 25 Oct 2017 

Oct 24 (Reuters) - Savara Inc :Savara announces proposed public offering of common stock.  Full Article